CDC-Derived Exosomes for Arrhythmia Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for ventricular tachycardia and fibrillation, such as antiarrhythmic drugs and radiofrequency ablation, often lead to adverse effects and increased risk of death, heart failure, and hospitalization, with limited ability to reduce scarring and arrhythmia risk without long-term toxicity and systemic tolerance.
Innovation Solution
Administration of cardiosphere-derived exosomes, which are extracellular vesicles capable of reducing the propensity for lethal ventricular arrhythmias by regrowing healthy heart muscle and targeting isolated late potentials, providing a less destructive alternative to traditional treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiarrhythmic drugs are used to treat ventricular tachycardia, then arrhythmia suppression is improved, but long-term toxicity and systemic tolerance increase
Solution Approach 1:
The invention extracts and isolates the therapeutic exosomes from cardiosphere-derived cells, separating the beneficial regenerative components from the harmful effects of systemic drug administration. The exosomes are purified and administered locally to the infarcted myocardium, achieving arrhythmia suppression without the systemic toxicity associated with antiarrhythmic drugs
Solution Approach 2:
Exosomes serve as an intermediary carrier that delivers therapeutic molecules (proteins, lipids, nucleic acids) directly to the target tissue. This intermediary approach replaces direct drug administration, enabling precise local delivery to the infarcted area while avoiding systemic distribution and its associated toxicities
2Reliability
If radiofrequency ablation is used to treat ventricular tachycardia, then arrhythmia termination is improved, but myocardial necrosis and cardiac perforation increase
Solution Approach 1:
The invention replaces the mechanical/thermal ablation system with a biological regenerative system. Instead of using radiofrequency energy to destroy arrhythmogenic tissue, exosomes are administered to promote regeneration of healthy myocardium, substituting destructive thermal mechanics with constructive biological processes
Solution Approach 2:
The invention converts the harmful scar tissue and damaged myocardium into a target for regenerative therapy. Exosomes are delivered to the infarcted area to stimulate regeneration and repair, transforming the previously harmful necrotic tissue into a site of active recovery and functional restoration
3Object-affected harmful factors
If catheter ablation is used as alternative to AAD therapy, then drug toxicity is reduced, but new arrhythmias and cardiac perforation increase
Solution Approach 1:
The invention changes the therapeutic parameter from destructive ablation energy delivery to constructive exosome-mediated regeneration. By altering the fundamental treatment parameter from thermal/mechanical destruction to biological regeneration, the invention achieves arrhythmia treatment without inducing new arrhythmias or structural damage
Data Source
AI summary
Described herein are compositions and methods related to use of exosomes, including cardiosphere derived cell (CDC)-derived exosomes for treatment and prevention of heart related disease and conditions, such as ventral arrhythmias, such as tachycardias. CDC-derived exosomes delivered by endocardial injection can diminish the total amount of isolated late potentials associated with an isthmus of slow conduction, while reducing the isoelectric interval between late abnormal ventricular activity and decreasing the incidence of inducible ventricular arrhythmias, thereby providing a biological treatment for arrhythmias which otherwise requires therapeutic interventions with adverse effects.